Total revenue for the first six months of 2010 was $11.7 million, up from $7.7 million recognized during the first half a year of 2009. The increase in revenue for the second quarter and first six months of 2010 was due to growth from revenue of the INTERCEPT Bloodstream System. Product revenue for the INTERCEPT Bloodstream Program was $5.7 million during the second quarter of 2010, representing an increase of $1.8 million, or 47 percent, from the second quarter of 2009. Despite average forex rate erosion of 8 percent between your U.S. Dollar and the Euro, product income grew by 4 percent from the first one fourth of 2010. Product income for the first half a year of 2010 was $11.2 million, up from $7.0 million through the first six months of 2009.I am especially thrilled to see Patient-Self Administration Solutions is currently open to payers, providers, and patients over the U.S., said Mindy Smith. The models and innovation of care developed from the Basis’ s study are invaluable and I will continue to support the building blocks and APhA as a pharmacist, member, patient and donor treatment advocate. During Ms. Smith’s tenure APhA Base marked a milestone with the recent start of its innovative PSM Solutions. PSM Solutions can be a proven model that can reduce overall annual price of diabetes care by approximately $1,000 per patient, improve wellness outcomes and increase individual satisfaction. Under Mindy’s leadership APhA Base strengthened its visibility and recognition while a national leader used based study and demonstrated a collaborative care model for sufferers with chronic conditions may improve health outcomes by empowering patients to become actively involved in their healthcare, said APhA Foundation Table of Directors President, Ed Hamilton, PharmD, FAPhA.